Biogen Inc. (BIIB) Earnings Call Transcript & Summary
April 24, 2024
Earnings Call Speaker Segments
Chuck Triano
executiveThank you, Jennifer. Greetings, everyone, whether it's morning, afternoon, or evening where you are, and I'm glad to have you join us for Biogen's call covering results from the first quarter of 2024. Prior to starting, please note that the earnings release along with the associated financial tables — among them our GAAP financial measures and a reconciliation to the GAAP and non-GAAP financial measures we'll be discussing today — can be found in the investors section of biogen.com. Tables one and 2 contain our GAAP financials, while table 4 provides a reconciliation of our GAAP results to non-GAAP financial results. In our view, non-GAAP financial results give a better picture of the continuing economics of the business and show how we run it internally. The slides we'll reference during this call have also been posted to our website. Keep in mind that forward-looking statements will be made, which rest on our expectations; such statements carry certain risks and uncertainties, and actual results could differ materially. For further detail, I'd urge you to review the risk factors covered in our SEC filings. Joining me today are our President and Chief Executive Officer Chris Viehbacher, our Head and President of North America, Alisha Alaimo, our CFO, Mike McDonnell, and Dr. Priya Singhal, Head of Development, who is here and will take part in the Q&A session. Opening remarks will come from Chris, Alisha, and Mike, after which we'll begin the Q&A session. So that we can address as many questions as possible, we ask that you please keep to one question. With all of that covered, I'll hand things over now to Chris.
Chris Viehbacher
executiveAppreciate that, Chuck. Morning, everyone. It's genuinely wonderful to report earnings per share growth for our first quarter. Not once in quite a few years has Biogen's core business performance put us in a position to truly show an increase in earnings per share, so this marks a significant milestone; plainly, plenty of work remains ahead of us, yet it does feel as though the company is turning a corner. On that note, I want to use this moment to express gratitude to my colleagues at Biogen. We've brought about an enormous amount of change inside this organization, and I thank them for sticking with it, for their dedication, their enthusiasm, and their tolerance through all of it. Still, I believe some of that transformation is now visible in these figures. Our effort has been to inject far more focus and discipline into placing our resources behind the things that matter and generate value. Something you might not notice is just how much reinvestment is taking place. An early manager of mine once shared a piece of wisdom: in this industry, you cannot cut your way to prosperity, and that couldn't be more accurate. Saving money isn't truly what we set out to accomplish. The Fit for Growth initiative, which, as these figures show, remains on track, will deliver $1 billion in gross savings along with $800 million in net cost savings and, moreover, $800 million of additional cash flow by the close of 2025. What we genuinely aimed to do was reshape the organization. For decades, this business has been intensely concentrated on our multiple sclerosis franchise, and now we're in the midst of launching four first-in-class new medicines, so we truly had to ensure those launches get proper support. Indeed, notwithstanding the expense cuts and margin gains that Mike will describe in greater depth, hundreds of millions of dollars sit behind these new launches as investment. Even though our total research and development spending has gone down, this sharper focus has in fact let us direct more money toward those assets where our conviction runs deepest. This goes well beyond simply trimming costs. It amounts to a redesign and, to some extent, a cultural shift. Let's turn to a few of these new launches. Clearly, the one drawing the most attention is LEQEMBI, so let's move to that slide. There are multiple ways to examine this. To start, obviously, the quarter-over-quarter trends look quite strong. As you've observed, patients on drug have grown 2.5x relative to where we ended the fourth quarter. Our in-market revenue nearly tripled in Q1 compared with Q4 of last year. That clearly matters. Yet what truly matters to me when I study this is not merely that. I've spent 3.5 decades working in this field. At this point, I couldn't tell you how many product introductions I've witnessed. Yet this particular launch is unusually tough, and the main reason is that the scale of change doctors are confronting here is genuinely enormous. When I visit hospitals and speak with physicians, as well as with people who interact with other physicians, it becomes quite clear that even getting that very first patient started on therapy involves a tremendous number of obstacles. At a single hospital we visited, securing permission merely to bring on a nurse who could assist with navigating the system required three months. Over at a different large medical center, accessing the infusion beds meant they had to put together a five-year business plan. Then you have the ambiguity surrounding reimbursement for PET scans — even though CMS had issued clarification and many of the MACs had followed through, pushing that clarity all the way down the channel remained quite difficult. What gives me real encouragement when I examine these figures is that despite all these obstacles, and despite the substantial time commitment required from physicians — and to their credit, many of those physicians are putting in that time without necessarily being compensated for it — they are still getting it done. They're pushing past these hurdles and barriers. And I believe that's what matters so much. When they look at patients — accomplished individuals who are cherished by their families — and watch this terrible illness gradually take the patient away day after day, they recognize the need. So I genuinely believe we're witnessing a great deal of momentum here. Again, a huge amount of credit belongs to the neurologists and to these centers for surmounting these difficulties, and I believe that will let us keep seeing growth from one quarter to the next. It might not follow a perfectly straight line, and Alisha will provide more specifics on that. But putting these protocols into place takes time. Even after you get that first patient, the pattern has tended to be, let's start with a handful of patients so we can get comfortable with the system. Once all of that is finished, though, we begin to see volume come through. One fascinating aspect of this launch is that normally we treat revenue as a proxy for demand. In this case, that connection isn't so straightforward, because this upfront time has to elapse before revenue comes through. I think that's another thing we're now observing in this first quarter — we're actually seeing somewhat more of that connection between demand and revenue. Underneath all of it, once those processes are established and once physicians are prepared, there's unmistakably underlying demand there. That, I believe, has really bolstered our confidence to increase investment at this point. A 30% expansion is planned for our U.S. field force. I'd add that this launch truly only got underway on 1st of September. And even at that point, one could make the case that we weren't entirely in a position to launch, since reimbursement for the PET scan had not yet been secured. That said, our U.S. teams at both Eisai and Biogen have put in an enormous amount of effort examining the data from the launch's first seven months. At this stage, we're essentially looking at shifting some resources around as we determine what matters and what doesn't. The teams, I think, are collaborating very effectively. Several new components of our promotional mix are set to kick in as we move through the second quarter. Speaking from Biogen's perspective, any forecasts would be premature right now. We'll be watching those month-over-month new patient starts along with revenue growth. Still, I'd definitely say the progress so far has me extremely encouraged. If I may pivot to another key growth driver, that being SKYCLARYS.
Chris Viehbacher
executiveAlisha will once more get into greater specifics, and I believe she'll also demonstrate to investors how our progress stacks up against other comparable cases, since the rare disease sector doesn't follow the usual patterns seen elsewhere. In rare disease, you invariably have a backlog of patients. So it takes time before that backlog moves through the system, and only afterward can you examine what the true underlying demand looks like. Keep in mind these aren't people who are simply sitting around in waiting rooms, and an enormous effort is required to locate patients. I'd say that's genuinely one of Biogen's strong suits; it's what, in my view, gives me the assurance to keep investing further, because I truly believe there's real expertise inside Biogen, and that's among the reasons we're aiming to expand a rare disease franchise. That said, we now have 1,100 patients receiving therapy in the U.S.; that figure is truly substantial. Yet I'm equally heartened by how the European launch is going; we already have — and bear in mind, this drug only won approval at the end of January — and still, 300 patients are already on treatment. Of course, you're all familiar with Europe: reimbursement must be secured nation by nation, and early access programs exist. For certain of those, revenue can be charged. For others, we cannot. Even so, reimbursement dossiers have already gone in for five EU countries. So my sense is Europe will contribute more and more to revenue; it's likely a 2025 narrative rather than a 2024 one. Still, judging by the acceptance and the uptake, that launch has likewise gotten off to a strong start; we're aware there are a great many patients across Latin America, and submissions have already been made in Brazil, for instance, with Argentina to follow. I believe that will prove a significant advantage and opening for us too. Keep in mind, Asia has no patients, since this is a genetic condition that predominantly impacts those of European ancestry. Actually, it was rather fascinating. I spoke with a key opinion leader based in Germany who has in fact conducted genetic research. Essentially, you simply trace the path the explorers took, and that's where patients will be found. With that said, let's dig a bit deeper, and I'll hand things over to Alisha.
Alisha Alaimo
executiveThank you, Chris. Good morning to all of you who are able to be with us on today's call. I'm Alisha Alaimo, and as Chuck mentioned, I oversee our North American business. This marks a truly distinctive moment in Biogen's history, with several first-in-class medicines launching across the U.S., which hands us a chance to bring about our return to growth. For our team, it also carries real meaning to stand behind more individuals living with Alzheimer's, Friedreich's ataxia, and postpartum depression. We figured it could be useful to offer a view on the market dynamics surrounding these launches and to explain how we're pursuing a tailored approach to help patients gain access to our therapies. I'll begin with the Alzheimer's market. Chris mentioned earlier that we're seeing a lot of large health systems around the country move ahead carefully, in deliberate stages and phases—meaning they're setting up their care pathways so that patients can begin diagnosis, treatment, and monitoring. Our sense is that we're at a point now where certain IDNs are moving past that initial stage and shifting their focus toward broadening and building out their model. Across Q1, a number of IDNs in different regions increased the number of patients they're handling. Among the 100 IDNs we prioritize, units in the first quarter rose to more than three times what they were in the fourth quarter, and that pushed our overall estimate of patients on therapy to about 2.5 times higher in quarter one compared with quarter four. Our view is that this uptick in new patients really began showing up toward the close of the quarter — take March, when more than 20% of the new patients added since launch came in. Right now, of the 100 priority IDNs we have, more than 80% have gotten LEQEMBI cleared via their P&T process, and nearly 85% of the IDNs holding that approval have submitted an order. Chris also pointed out that a growing number of physicians are gaining familiarity with LEQEMBI. The number of unique prescribers during quarter one came in at twice what it was in quarter four; our sense is that we remain in the early stages of realizing the opportunity to treat a large volume of patients across the priority IDNs. It might be helpful to walk through a few illustrations of how this plays out at individual sites. Take a sizable Midwestern health system that put LEQEMBI on its formulary last July. When Q1 began six months afterward, that system had placed orders for just 300 units. Yet once March wrapped up, its orders had climbed to 2,700 units. Much like the case I just described, a Southeastern health system also brought LEQEMBI onto its formulary during August of 2023. As Q1 got underway five months afterward, roughly 560 units had been ordered by this system. Then, before Q1 closed, this system's orders exceeded 1,750 units for treating its patients. To give you some context, a neurologist network in that same area that operates locally placed orders for 3,000 units over that identical stretch of time—possibly because they've managed to scale up how they work so they can serve more patients. Even with that, our belief is that this notable Southeast IDN plans to expand beyond its primary care site and provide treatment to patients in multiple locations—one more example of how IDNs are growing and broadening their footprint. From what we can see, many systems are just now wrapping up the staging period, and the recent trends, in our estimation, confirm what we've consistently stated: that across the medium to longer term, LEQEMBI represents a substantial commercial opportunity. Since access and infrastructure keep advancing and patient volume keeps climbing, we also feel the moment is right to grow the field force. Teams at Biogen are in the process of recruiting a customer-facing field group that will become part of HI. At the same time, to get the patient community engaged, Biogen and HI have rolled out fresh direct-to-patient and caregiver omnichannel marketing efforts. These digital initiatives and point-of-care tools target patients who already have a diagnosis and who, in our view, are being looked after by a neurologist. Given these encouraging signals, we can't wait to share further updates down the road. Now, on SKYCLARYS—we believe this launch is delivering strong results, because we continue to beat the penetration levels typically observed in most rare disease launch benchmarks. By April 19th, over 1,100 patients were on treatment. Given about 4,500 treatable Friedreich's ataxia patients in the US, that puts us at 24% penetration—ahead of even our own impressive Spinraza launch. In rare disease launches, it's common to move beyond the initial backlog and start reaching more people who were diagnosed earlier with Friedreich's ataxia, or who are suspected to have it. The patient count may fluctuate, but we anticipate adding patients each month. During the last quarter, we described how we've brought together some of our advanced rare disease capabilities to improve access, logistics, and patient support. In particular, our market access team kept gaining ground on securing favorable policies in quarter one. As of today, SKYCLARYS reimbursement now covers close to 80% of all U.S. pharmacy lives. These efforts around patient support and access matter greatly in helping patients begin therapy as early as possible and stay on it over the long term. Now that we have a meaningful base of patients on therapy, we're concentrating on two key areas in this next phase of the launch. First, teaching community neurologists and PCPs about Friedreich's ataxia and SKYCLARYS. Second, bringing in more suitable patients. I'll start with what we're doing for HCPs. Keep in mind that with Friedreich's ataxia, besides patients being clustered at the leading centers of excellence, we believe they're also receiving treatment in the community. To help these physicians, we've widened our field footprint, and we're applying AI to examine data so we can connect with HCPs who might have patients not yet treated. By understanding which sites of care are relevant and when patients last saw their physician, we think we can assist more patients even faster. Through genetic testing, we expect patients can verify a possible diagnosis and figure out whether SKYCLARYS is an option for treatment. When it comes to getting patients activated, the real-world stories people are posting on social media give us encouragement. Based on what we've seen, those accounts can be useful to other people who have received a diagnosis. A lot of these narratives regarding what SKYCLARYS can do mention slower disease progression and, for certain individuals, even long-term symptom improvement; beyond these organic posts, we expect to roll out our SKYCLARYS social media campaign before long. So our view is that we've made a solid beginning, though we recognize that additional people with Friedreich's ataxia could still benefit from our help, and we're eager to provide that support. That leads me to ZURZUVAE. Like Chris said, the launch's results so far give us encouragement, and we believe multiple favorable trends are emerging around providers, patient experience, and reimbursement. Let me start with providers. Among various physician categories, our sense is that a lot of them are showing a readiness to treat without delay. In particular, OB-GYNs accounted for the most prescribing overall in quarter one, which strikes us as encouraging since they frequently are the ones who first encounter PPD patients. On top of that, the breadth of adoption keeps expanding. During March, the count of HCPs who prescribed ZURZUVAE was almost twice what it was in January alone. We've observed that certain early prescribers need just a handful of calls prior to treating. Remember that ZURZUVAE is a scheduled product that you get through a specialty pharmacy.
Alisha Alaimo
executiveWe recognize that psychiatrists typically know how to collaborate with specialty pharmacies, but for a lot of OB-GYNs this may be an unfamiliar procedure; we are focused on teaching those providers about what needs to happen so they can assist the right patients. Next, certain HCPs who gained early experience with ZURZUVAE have told us that a number of their patients described meaningful relief from depressive symptoms just days after beginning therapy. A number of patients are posting about their own 14-day journeys with treatment on sites such as TikTok, and we think their bravery in speaking out will help raise awareness among other women dealing with postpartum depression. Third, our sense is that we are advancing well when it comes to government and commercial access. A lot of payers already have policies established, and most of those have been favorable, while certain others keep covering ZURZUVAE even in the absence of formal policies. Coverage for ZURZUVAE without excessively onerous restrictions is being provided by two of the three national pharmacy benefit managers. Discussions are ongoing and active with the third national PBM while we wait for their choice. And although Medicaid often moves more slowly, nearly 50% of states, among them a few of the biggest, sped up reviews into quarter one, which we consider atypical for a process that after FDA approval can generally stretch to as long as a year. It is encouraging to us that roughly two-thirds of Medicaid lives under published policies seem to face only minimal access restrictions. We expect the rest of the states to examine coverage across 2024, and we will keep backing their reviews to the greatest extent we can. Prior to turning things over to Mike, I want to emphasize that we carry a major obligation to assist those living with Alzheimer's, Friedreich's ataxia, and postpartum depression, and we are acting with urgency to serve these patient communities. Our belief is that we are achieving meaningful progress toward that mission, and we are eager to keep bringing you updates. So with that, I will now hand things off to Mike.
Mike McDonnell
executiveThanks, Alisha, and greetings, everyone. I want to begin with a broad look at where we stand financially and how that progress looks through the lens of our Fit for Growth program; we stay intently focused on lifting profitability as we work to bring this company back to growth in both EPS and revenue. Keep in mind that every financial comparison I give is against the first quarter of 2023. Turning to the top line, the four products we recently launched brought in revenue during the first quarter, and that was more than enough to counterbalance a 4% drop in our MS business. As we mentioned on our last earnings call and at a recent webcast investor conference, we anticipate that revenue this year will lean more heavily toward the back half, and we attribute that to both the shipment schedule for SPINRAZA outside the U.S. and the growth trajectories we expect from our newly launched products. On gross margin, we improved by 5 percentage points this quarter as our revenue mix has changed. The reason is that higher-margin product revenue is increasingly taking the place of lower-margin contract manufacturing revenue. We also recorded $45 million in idle capacity charges during the first quarter of 2023, and there were none in the first quarter of 2024. Our R&D prioritization and Fit for Growth initiatives clearly affected our non-GAAP R&D and SG&A expenses, which we call core OPEX, this quarter, and the result was a 13% decline versus a year ago; those savings helped drive substantial growth in our non-GAAP operating income, which rose 24% year-over-year. Our operating margin came in at 31% for the quarter, compared with 23% in the first quarter of 2023. Though these improvements are encouraging so far, we think additional work remains that can be done to keep making these metrics better. Now some further detail on how revenue behaved in the first quarter. Total revenue reached $2.3 billion, down 7% on both an actual and constant currency basis. Revenue for our MS franchise fell roughly 4%, pulled down by competition and the typical channel seasonality we experience in the first quarter. Inside MS, VUMERITY revenue climbed 18%, helped by global patient growth along with some favorable channel dynamics during the first quarter. As for TECFIDERA in the EU, most generics have now left the market, which produced 5% ex-U.S. growth for TECFIDERA this quarter. We still believe we hold entitlement to market protection in the EU through February of 2025. And now a brief deeper look at our rare disease revenue for the quarter. SKYCLARYS brought in $78 million of revenue, including roughly $5 million in Europe, where launches are underway in several countries. For SPINRAZA in the US, revenue rose 1% this quarter, and we continue to be encouraged by the resilience there. SPINRAZA revenue outside the US fell 35%. Most of that year-over-year decline stemmed from shipment timing in certain emerging markets. We keep observing patient volumes that are broadly steady around the world, and we anticipate that the shipping situation beyond the U.S. will mostly settle down across the rest of 2024; on top of that, during the quarter we experienced a few small adverse effects stemming from competition as well as foreign exchange. Looking at all of 2024, we anticipate that worldwide SPINRAZA revenue will fall in the low single-digit % range. ZURZUVAE brought in $12 million of revenue, and we think that figure includes a certain amount of channel stocking ahead of rising demand, something typical of any new launch; and finally, contract manufacturing revenue came in considerably below the prior year. And just as we accounted for in our full-year guidance, we still anticipate that this line's contribution will be much smaller than a year ago, since we wrapped up several batch commitments during 2023. Non-GAAP cost of sales for the first quarter equaled 22% of total revenue, an improvement of 5 percentage points. As I said earlier, this gain came about because of a more favorable product mix, as revenue from new product launches took the place of lower-margin contract manufacturing revenue, and it was also tied to reduced idle capacity charges. We recorded none during the first quarter of 2024. Non-GAAP R&D expense for the first quarter fell by $124 million, mostly because of savings delivered through Fit for Growth, and we remain on track there to realize cost savings of $1 billion gross and $8 million net of investment by the close of 2025. We additionally saw savings stemming from our R&D portfolio prioritization, which has made a significant difference as we halted certain programs and concentrated our spending on areas we think carry a greater chance of success. Non-GAAP SG&A expense declined by roughly $33 million during the first quarter, chiefly because of $50 million in G&A-related cost reductions that were realized in 2024 under our Fit for Growth program, and that was offset by higher operational spending on sales and marketing efforts supporting the LEQEMBI and SKYCLARYS launches. I should also point out that the prior year contained $31 million tied to ending a co-promote agreement for our MS products in Japan. Taken together, all of this drove non-GAAP operating income up 24%, with non-GAAP operating margin now exceeding 30% and still rising, along with non-GAAP EPS growth of 8%. Now, a quick update regarding our balance sheet. We finished the quarter with about $6.5 billion of debt, $1.1 billion in cash and marketable securities, and net debt of approximately $5.5 billion. As of March 31st, 2024, that $6.5 billion of total debt included $250 million of the $1 billion 2023 term loan, which was arranged when we acquired Reata. As of March 31st, 2024, we had paid back $750 million of this $1 billion facility. The outstanding $250 million is anticipated to be repaid in the second quarter of this year, so during this quarter, sooner than we originally expected, which had been by the close of this year. I should point out that the cash and marketable securities total excludes a $437 million payment from Samsung that came in earlier this month. During the first quarter, we kept producing robust free cash flow, at roughly $507 million. So all in all, our balance sheet is still in a solid spot, with growing room to put money into growth initiatives. As for the strategic review of the biosimilars business, so far we have not gotten an acceptable offer from a third party. That process is still underway, and we will stay disciplined while we keep looking at every option, which includes keeping the business. Moving on, I want to talk about our full year 2024 guidance ranges and assumptions. We are reaffirming our expectation for full year 2024 non-GAAP diluted earnings per share of between $15 and $16, which reflects expected growth of approximately 5% at the midpoint of the range as compared to 2023. Every one of the prior assumptions behind our guidance, including the ones shown on this slide, is unchanged. Let me remind you that we have potential R&D success milestone or opt-in payments tied to the upcoming clinical data readouts, and we have built an allowance for some of these potential payments into our guidance. Naturally, whether they get paid will hinge on the data and the decisions we make as a result. Lastly, we just announced that we completed a sale of one of our two priority review vouchers for $103 million. Right now, we expect to set these proceeds aside for business investment or to back business development opportunities as they come up. To wrap up, we stay committed to our number one goal of returning Biogen to sustainable top and bottom line growth and creating long-term value for our shareholders; we will now open up the call for questions.
Chuck Triano
executiveThanks, Mike. Jennifer, can we go to questions?
Eric Schmidt
analystHello, and I appreciate the updates and the chance to ask my question. Regarding LEQEMBI, and this may be for Priya, there were a few developments over the past month or so — the EMEA postponement concerning the CHMP recommendation. Additionally, I realize this falls under your partner's responsibility, but Eisai stated they were unable to seek Sub-Q approval before completing the immunogenicity study. Could you bring us up to date on the schedules for those two efforts moving forward? Thank you.
Priya Singhal
executiveCertainly, and thank you, Eric. Let me begin by noting that we're collaborating with Eisai to give patients the choice of a subcutaneous version. Everything we do is grounded in data. Seeing the bioequivalence was highly encouraging. We convened last year and presented that information at CTAD. That represented the key achievement. After that, we've been in discussions with the FDA. To explain where we stand, we've divided our approach to the subcutaneous formulation. The priority is to pursue a rolling submission for a subcutaneous autoinjector intended for maintenance. We'll do that as soon as possible. Eisai has submitted a fast-track request already. We're waiting on that. Once it comes through, we'll file while we keep generating the three-month immunogenicity data the FDA asked for. Next, since exposure from the subcutaneous version exceeded that of the IV version, we think optimizing the dose serves patients' interests and will deliver greater convenience. So we're refining those doses, work that is already underway and continuing throughout this year. On scheduling, should the fast-track for subcutaneous maintenance be granted, we'll submit right away for rolling review, which we anticipate happening this year, and even without fast-track we'll still file because the three-month immunogenicity data will be complete by Q4. For subcutaneous induction therapy, we anticipate filing by the first quarter of 2026, which Eisai already shared in their investor remarks in early March. I'd also remind everyone that we finished our intravenous maintenance filing by Q1 of 2024, consistent with our target. Thank you.
Chuck Triano
executiveI appreciate that, operator. Let's take the next question.
Paul Matteis
analystMorning, everyone. Thanks for letting me ask. I'd like to hear how you're now viewing business development when it comes to capacity, therapeutic area, stage of development or commercial — and within that frame, in what way does the somewhat unpredictable yet encouraging path of Lecanemab shape your willingness to act on something at present rather than perhaps hold off until 2025? Thanks.
Chris Viehbacher
executiveThank you, Paul. My sense is that during this year, business development will be our focus as we look to add new assets, in both early-stage research and development. We've consistently described ourselves as a neuroscience company, yet the truth about neuroscience is that it carries high risk. The fundamental disease biology isn't always something we grasp. These diseases move ahead slowly, which pushes you toward trials that are very lengthy and costly. Frequently you cannot run a proof of concept study during phase II ; therefore, even though neuroscience remains an area we're dedicated to, speaking for myself, I believe that for a business of our size, it simply isn't diversified sufficiently. That's why we already indicated last year a desire to move into certain rare disease adjacencies. In rare disease, I'd say we truly possess an outstanding commercial capability. There are unique commercial demands, at times a need to assist with diagnosis, every one of the payer obstacles that must be gotten past, and naturally, locating the patients. There's a great many tools that I believe we need in order to accomplish that; then there's immunology. From the very beginning we've been an immunology company, given that MS is essentially an autoimmune disease. So I expect we'll take the chance through licensing collaborations to grow that. Considering where our balance sheet stands, if something truly remarkable were to appear, from our standpoint, but given our current position, I don't believe we'd be contemplating any acquisition activity this year, at least nothing of significant size; however, Mike, perhaps you could address what the balance sheet can support.
Mike McDonnell
executiveOkay, Paul, one thing I’d add is that our balance sheet is sitting in a really strong position. When you take our net debt at the close of the first quarter and adjust it on a pro forma basis for both the Samsung payment and the term loan paydown we’ll complete in the second quarter, that comes to roughly $5 billion of net debt; meanwhile, we produce around $3 billion of EBITDA. That means leverage is only somewhere from one and a half to two turns. So for something we liked, we could definitely take on an additional turn of leverage, at least on a temporary basis, and since we throw off a couple billion dollars of free cash flow each year, I tend to think of 2024 as offering maybe $4-$5 billion of capacity for things we’d be genuinely interested in. Then, if you were considering something closer to Reata, that probably makes a bit more sense from a capacity standpoint in 2025 or later.
Chuck Triano
executiveThanks, Mike. Chris, can we take the next question, please?
Salveen Richter
analystMorning, and thanks for taking my question. Regarding SKYCLARYS, can you discuss what you expect for 2024 and whether any bonus dynamics have had an effect on that? And more specifically, you mentioned being at 24% penetration of the U.S. market. What's your view on peak penetration in the U.S., and then what do you expect for the pace of uptake in Europe and net pricing there? Thank you.
Chris Viehbacher
executiveWould you like to handle the U.S., and then I can add on Europe?
Alisha Alaimo
executiveRight. So, if you consider the U.S. and how far we've reached in terms of market penetration — and you likely noticed the analogs shown on the slide — the launch has performed really well up to this point. And like I mentioned, we've already gotten through what you might call the catch-up population. There are plenty of strong initiatives we currently have running, and we're rolling them out simultaneously to find and ideally reach the remaining patients. That said, the way we view this market is that there are two groups of patients. One group is very actively involved with their doctors, while the other group likely hasn't had any engagement for somewhere between the past two and five years. We possess sufficient data and analytics to pinpoint precisely where those physicians are located and how patients have progressed through them. Because of that, we're now locating many of these practices, particularly out in the community, that might have one or two patients who could be diagnosed with general ataxia rather than Friedreich's. So what I mentioned earlier during this call is that we're expanding the footprint of our field force. And we're taking a highly targeted approach toward these practices so that, once again, we can boost market penetration. Now, as you can see, with a product like SPINRAZA, we've also done quite well and achieved a fairly strong level of market penetration with that product, despite the fact that competitors exist in the marketplace. With SKYCLARYS, since there's essentially no competitor in the market, we anticipate continuing to penetrate this over the coming several years for as far as we're able to go. We're aware that roughly 4,500 patients could have Friedreich's ataxia, so what we're doing is planning everything within our power to reach as many of those patients as fast as we can.
Chuck Triano
executiveThank you, Alicia.
Chris Viehbacher
executiveYeah, and regarding Europe, in certain respects, single-payer structures are genuinely perfect for uncommon conditions. Many patients in the U.S., even when reimbursement exists, even when insurance coverage is in place, face a tremendous number of obstacles that the American healthcare system places on them. And many of those we don't truly encounter in Europe. So I believe we're witnessing swift adoption. Once more, there's a population playing catch-up; and there's a distinction between patients receiving treatment and patients producing revenue; so initially, we actually have the commercial launch in Germany since we can secure reimbursement fairly fast. Additional nations will come online as we move through each country's reimbursement procedures; but our aim is actually to grow the patient base. So there's a number currently on free drug via these EAPs, and some of the EAPs allow you to charge. So it's going to be somewhat uneven when we look at the revenue line. But I'd say we're hugely encouraged by patient uptake; and then outside the U.S. in Latin America, that might well be a 2025 story. I think we could see our first launch in Brazil during the early part of 2025.
Chuck Triano
executiveGreat. Thanks, Chris. Can we move to the next question, please?
Umer Raffat
analystHello everyone. I appreciate your time in addressing my question. I'd like to direct one to Priya, if that's alright. I'm aware that this summer brings the late-stage lupus data with the CD40 ligand antibody. It's also my understanding that the measurement point for these results is week 48, not week 24. So my question, I suppose, given the absence of a distinct dose response for efficacy in the earlier trial, is whether you could discuss how the effect on B-cells varied across the doses, and if the extended timeframe might genuinely enhance that B-cell effect in the readout that's coming? Thank you.
Priya Singhal
executiveThank you, Umar; we've examined the phase II trial in great detail, and we made the choice to incorporate the 48-week endpoint based on BICLA for this phase III trial. In the end, what we seek is a meaningful shift on the primary endpoint as well as the key secondary endpoints for SLE, including prevention of severe flares and patients reaching low disease activity. We also believe BICLA is a sensitive and clinically meaningful composite gauge of SLE disease activity, one that demands improvement across every body system among those with moderate or severe activity at baseline, with no worsening and no need to increase background medication. We altered the study. We've honed the patient population, and we believe this will prove truly significant as we anticipate the readout. Another thing, I think, to bear in mind here is that we thought about ways to adjust the population for this trial and arrive at an answer very swiftly so we might potentially get Dapi to patients. I trust that responds to what you asked.
Chuck Triano
executiveThanks, Priya. Let's go to the next question, please.
Michael Yee
analystHi everyone, thanks. I’d like to go back to the SKYCLARYS remarks. I realize you mentioned the intention was to bring on patients each month. Could you discuss how SKYCLARYS is expected to trend over the course of this year, including any offsets such as rates of discontinuation and so on? In what way does that play into it? Also, are you going to record revenues from Germany during this year? So please address the revenue dynamics for SKYCLARYS. And if I can ask one quick clarification, Priya referred to a Sub-Q induction filing for LEQEMBI in Q1 2026. I just wanted to confirm that is what she said. Thank you very much.
Priya Singhal
executiveYes. The outcome and the filing will fall within that period; but we'll share more about this after we optimize the dose and proceed.
Michael Yee
analystAll right. And what about SKYCLARYS?
Priya Singhal
executiveYes. Regarding SKYCLARYS, I'd say it's really complex when you look at it on a month-by-month basis, since there are obviously patients we're bringing in through the start forms, and for that deeply committed group, we're essentially hitting the ceiling at this point. We know precisely who those individuals are, and we've reached them by way of the physicians. Yet at the same time, a rate of discontinuation is going to exist, just as you pointed out. Plus, some patients are going to be moved off the start forms and placed onto the product; and naturally, they might skip a dose or two, correct? So compliance becomes a factor as well. That means from one month to the next, things will be uneven, since you might say you've gained 50 patients, yet other forces are at work within that patient population. As for what we expect over the year — and I'm unable to provide a precise figure — we will keep adding patients each and every month; we can locate those individuals within the community, and additional pluses and minuses affect those figures. Ultimately, we'll make certain we remain ahead among the rare disease analogs and that we achieve market penetration.
Chris Viehbacher
executiveRight. And over in Europe, revenue is now being recorded for Germany. Plus, we've rolled out in Austria along with the Czech Republic too; and across certain countries, we're in a position to actually bill for early access programs in Europe, and a portion of that money will flow through as well; though what you'll likely witness is fuller EU-wide revenue as a region during 2025, yet contributions to revenue in 2024 from specific European countries will definitely be there.
Chuck Triano
executiveGreat. Thanks, Chris. Let's go to the next question, please.
Colin Bristow
analystMorning, everyone, and thanks for having the questions. Perhaps I'll take one about how the LEQEMBI commercial operation is set up. A worry among investors—and significant input that doctors have been giving us—centers on the sales and marketing footprint seeming smaller than what people might have anticipated. In your prepared remarks, I caught that you're forecasting a 30% expansion of the U.S. footprint. Could you put a number on what the U.S. commercial footprint looks like right now? Also, did you always intend this 30% increase, or did it come out of a review showing the existing footprint fell short? Thanks.
Alisha Alaimo
executiveI appreciate the question. When you pull back and consider how we approached this launch from a strategic standpoint, our consistent position was that it would be done incrementally. From the outset, we understood that bringing sites online would require time. We needed to await multiple signals from CMS, including complete authorization and the reversal of the NCD for PET. Given all of that, we didn't want to launch with an enormous sales team that couldn't genuinely influence or break into the market. So the choice made instead was to enter with a highly targeted strategy. We concentrated on the leading accounts that we believe manage most diagnosed patients, particularly those receiving neurology care; we stated that when the market reaches a point where we judge it prepared for expansion, that's when we would expand. Regarding your point about doctors reporting they aren't encountering much sales activity, I think we must also keep in mind the context that getting these sites operational demands substantial work. You also don't want three, four, or five separate individuals visiting these accounts to provide support; so we've stayed very deliberate about getting the big IDNs operational. Certain centers that stepped forward and were genuinely capable of moving fast, we brought them online. Now, as you observe the expansion happening at 30%, our primary focus will be the large IDNs that are currently launching their expand-and-extend satellite locations, where a bigger group of patients will be permitted to come through for diagnosis and treatment; so with this subsequent build phase, for which we believe we've conducted extensive analytics, and we've had numerous third parties offer input on what the proper sizing should be, we at ACI believe this will be the correct footprint to fuel the next acceleration of growth.
Chris Viehbacher
executiveAll right, I'll hand things over to Priya so she can address what Mike Yee asked about.
Priya Singhal
executiveThanks. Thanks. I simply wanted to make it clear that this is the result for fiscal year 2025 at ECI, which corresponds to Q1 2026, in the case of subcutaneous induction. Naturally, it might fall within a range, since it would entail an sBLA, possibly a priority review, and other such factors, all of which could move it. Even so, that is what has been communicated by ECI. I just wanted to restate that. Thank you.
Chris Viehbacher
executiveSo the outcome and not the filing?
Priya Singhal
executiveYes.
Chris Viehbacher
executiveObviously, earlier?
Priya Singhal
executiveEarlier.
Chris Viehbacher
executiveYes.
Priya Singhal
executiveI appreciate it.
Chuck Triano
executiveThank you, Priya. Let's proceed to the following question, if you would.
Brian Abrahams
analystHello. Morning. I appreciate you fielding my question. Regarding LEQEMBI Sub-Q and the FDA's ask for immunogenicity data, I'm wondering whether you have any insight into what prompted that request, how confident you are that PK will be linear at half the Sub-Q dose; and then at what point during treatment do you propose patients switch from IV to Sub-Q maintenance? Thanks.
Priya Singhal
executiveOf course. Thank you, Brian. So broadly, as you're aware, we had studied the 720mg in the naïve patient population from the Clarity AD open-label extension substudy for subcutaneous; and beyond that, we also had modeling data. That is the basis on which we're proposing 360mg as the weekly maintenance dose. The FDA simply wants more immunogenicity data. We view this as a sensible ask, and we're already working on producing it. So on the whole, we don't anticipate any question about bioequivalence. What this comes down to now is the immunogenicity and in fact gathering it from patients who would undergo testing for it. So that's our expectation there. Could you remind me of the second part of your question?
Brian Abrahams
analystAt what point do you envision individuals moving from intravenous to subcutaneous maintenance therapy? Is there evidence that backs up the timing of that switch during the treatment course?
Priya Singhal
executiveIndeed. I believe this matters quite a bit, since an intravenous maintenance filing has been submitted by us. That submission was finished in Q124. And truly, three separate sources of evidence underlie it: study 201, the phase two trial, the gap period, modeling, plus the open-label extension within the phase III. So those are the inputs behind our IV maintenance filing. And really, the FDA will join us in determining the right moment to shift from biweekly IV to once every four weeks. And beyond that, a discussion about subcutaneous maintenance will follow. So truly, the process is highly methodical, and the IV maintenance work must be fully cleared first. Meanwhile, SC maintenance proceeds in parallel. I hope that's clear.
Chuck Triano
executiveThanks, Priya. Let's move to the next question, please.
Jay Olson
analystOh, hi there. Thanks for giving us this update; it appears that relative to earlier quarters, you're putting more emphasis on your three commercial launches and somewhat less on the R&D pipeline. Is there a specific cause for that change in emphasis? And how much additional effort do you intend to put into optimizing your R&D portfolio? Thank you.
Chris Viehbacher
executiveWell, I'll begin. I mean, I believe we've got the first four data readouts arriving at midyear; so I think we expected we'd have more data; it stands to reason to bring the R&D back once we have more data. I'd say, in fact, from a prioritization standpoint and Priya, you can chime in here, but I think we've mostly completed the task of having projects that are either projects of conviction or projects where we're awaiting the data outcome; they're underway; and simply because of how neuroscience projects are, we must wait and see what the data tell us. I think you'll see us being far more disciplined regarding whether we move forward or not. Our go-no-go decisions, I believe, have all been plainly set out for those. I think the next task is really now to expand the pipeline, as I mentioned earlier, that we want to diversify our business somewhat more than we did previously. So Priya is definitely working together with Jane on considering what things we can additionally bring into the pipeline from outside. But Priya, I don't know if you'd like to add anything there.
Priya Singhal
executiveAppreciate that, Chris. I believe you nailed it — that's precisely correct. Our four readouts have us quite thrilled, and we're getting everything ready for them. The go/no-go criteria have already been sorted out. The remainder of the pipeline sitting in mid- and late-stage keeps us genuinely enthusiastic, especially BIIB080, our anti-Tau ASO, plus the 2 phase three programs we have in SLE — Litifilimab and Dapi, which we were just discussing — and Litifilimab is also in cutaneous lupus. A number of our projects are in early phase development, and we're working hard to stay very disciplined regarding evidence and database decisions.
Chuck Triano
executiveThank you. Appreciate it, Priya. Let's take the next question.
Chris Raymond
analystOh, thank you. I'd like to ask something strategic regarding your business development approach. Chris, I picked up on what you said about moving away from neurology into other areas. That's been a theme from you folks for some time, and your transactions have centered on fields outside of MS. Yet honestly, when you survey the broader industry, there's some reasonably promising early-stage innovation happening in MS. And despite your business shrinking, what our checks show is that Biogen is still regarded as a trusted company, and I'd contend there's substantial value tied to that market presence. So I suppose the strategic question is this: are your BD efforts driven by a belief that you must diversify beyond MS strategically? Or does it reflect that you simply haven't come across an early asset that's worth licensing? Or is there a different underlying factor in the MS market that's caused you to put other areas first? Thank you.
Chris Viehbacher
executiveWell, it's a bit of all of those things, really. First off, we have not walked away from MS. We do have early research programs there. The unmet need in MS has become much narrower; it's essentially the progressive form now, which is an extremely difficult indication to pursue. But we still have programs in ALS; and actually, I'd say the approval of QALSODY has demonstrated an incredible scientific accomplishment. It might not be a big financial accomplishment, yet it truly opens things up so the field can have a biomarker letting you determine if something works in ALS or not. So we have several ALS programs. We're in Huntington's. As you're aware, we have a Parkinson's program. We've got Tau, which along with lupus, we regard as high-conviction programs inside the company. So we believe—and I think you're correct—that we're very strongly positioned in neurology. I wouldn't limit it to MS, but neurology overall; however, the truth is we're sitting there with programs that are extremely hard to predict, extremely costly, and take a very long time. And when you consider our capacity to strike outside deals, that space is quite narrow too. There simply aren't many people operating in the CNS area. So we are in no way giving up on it. Actually, the very fact that we pursue these incredibly hard diseases is a genuine point of pride at Biogen. And I must say, I remain astonished by the capability and talent inside our organization. But the truth is we need R&D to deliver more predictable results. And I believe a great deal of that capability exists within the company. I can't envision us ever shifting course and making a left turn into oncology or anything of that sort. Yet I'd argue there's real credibility in our position within rare diseases as we move further into immunology. Honestly, what we've accomplished in MS and, for that matter, lupus really demonstrates this point. So my expectation is that we'll keep extending our reach. That said, it likewise widens what we can pursue when it comes to partnering, rather than merely spreading our portfolio across more areas.
Chuck Triano
executiveRight. Thanks, Chris. Can we take our last question, please, operator?
Terence Flynn
analystThanks a lot. Appreciate you fielding this one — perhaps a two-part question regarding LEQEMBI. Clearly, you mentioned that the count of unique prescribers grew by over 100% during this quarter. I'm curious how much additional reach you anticipate from growing the field force as we look ahead through 2024, and also whether you have any initial observations regarding how long patients are staying on treatment. Thank you.
Alisha Alaimo
executiveYes, thanks for asking. Regarding my expectations for the remainder of the year, when you consider the stages these IDNs currently find themselves in — and even with these smaller accounts, they tend to progress quickly out in the community. Taking a broader view and putting the IDNs into context: we received full approval in July. These very large systems needed roughly 6 to 8 months to get themselves organized, which is the staged, phased process I described; and given that they are now beginning to open additional sites for diagnosis and prescribing, my belief is that you will likewise observe a rising count of physicians writing prescriptions. And that figure will keep declining over the balance of the year. When you examine how many physicians we're going after versus the actual number prescribing, a sizable gap remains. So I expect that trend to persist, particularly as the field force arrives. Assuming they're covering, our aim is essentially to generate faster momentum at these large IDNs. I mentioned the priority 100 to you. But bear in mind, we in fact target considerably more than those. I simply continue to reference the priority group. And plenty of other IDNs are likewise prescribing and are likewise broadening and lengthening. The second portion of your question concerned
Terence Flynn
analystHow long they stay on it. How long they stay on it.
Alisha Alaimo
executiveHow long they stay on it. This is a fascinating one, and we've had numerous discussions with a lot of these prescribing sites. Doctors set out extremely clear and explicit expectations for patients — once someone begins this therapy, the understanding is that they'll come in for an IV infusion every 14 days and remain on the product. What we've observed so far, and what we think is going on so far, is that patients are remaining on the product. That's what we hear back from the physicians, and that's also what we hear back from the figures we look at, the data we look at. As far as how long they stay on it goes, the plan is that they're keeping patients on the product. I think questions exist out there about what should be done regarding how long they stay on it. But with no data available, physicians are keeping patients on.
Chuck Triano
executiveOkay, thank you, Alisha. And I appreciate everyone being with us on today’s call. The investor relations team will, as always, be around for any follow-up questions. Enjoy the remainder of your day.
Operator
operatorThis does conclude today's conference. We thank you for your participation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.